In this study, a high HbA1c did not reduce the occurrence of nocturnal hypoglycemia, and low HbA1c was not associated with the highest TIR. Optimal personalization of glycemic control requires the use of newer tools, including CGM-derived parameters (Diabetes Care)
Diabetes News
Category: Treatment
Structured self-monitoring of blood glucose is associated with more appropriate therapeutic interventions than unstructured self-monitoring: a novel analysis of data from PRISMA
Our data strongly support that structured SMBG has clinical value in reducing HbA1c in non-insulin-treated T2D and suggest that this clinical benefit may be mediated by more appropriate and timely changes in drug therapy (Diabetes Research and Clinical Practice)
Amplifying the antidiabetic actions of GLP-1: potential benefits of new adjunct therapies
Taken together, therapies that activate GLP-1 receptor signalling, in combination with various other cell signalling pathways, show potential for treating type-2 diabetes and obesity with superiority over GLP-1 receptor agonist therapy alone (Diabetic Medicine)
Individual, healthcare professional and system-level barriers and facilitators to initiation and adherence to injectable therapies for type 2 diabetes
A model is presented to help patients, health practitioners and policy makers identify barriers and facilitators and understand the complex interplay of physical, psychological and social factors involved when prescribing injectable therapies (Diabetic Medicine)
Heal Thyself: SGLT2 Inhibition Limits Regenerative Cell Exhaustion and Heals Damaged Vessels
Collectively, the study of Albiero et al. establishes novel mechanisms that clarify the critical role of BM-derived cellular subsets to directly enhance endothelial healing during diabetes (Diabetes)
Metformin for pediatric obesity and insulin resistance: a retrospective study within an integrated health care system
Metformin with lifestyle interventions significantly reduced weight, BMI, and BMI z score in pediatric patients with obesity and insulin resistance up to 24 months, compared with intensive and routine counseling alone (Obesity)
Glucose-Lowering Therapy in Patients With Postpancreatitis Diabetes Mellitus: A Nationwide Population-Based Cohort Study
PPDM is a common type of secondary diabetes in adults but is often misclassified and treated as type 2 diabetes, although PPDM requires special considerations for management (Diabetes Care)
Glucagon for hypoglycaemia treatment in type 1 diabetes
As novel and stable glucagon formulations are being approved and launched on the market, new possibilities for improved hypoglycaemia rescues and new treatment approaches emerge (Diabetes/Metabolism Research and Reviews)
Facilitated Buccal Insulin Delivery via Hydrophobic Ion-Pairing Approach: In vitro and ex vivo Evaluation
Overall, the study has revealed a feasible alternative for injectable formulations, and thus, the HIP-nanocomplex strategy could serve as a platform for buccal delivery of peptide drugs (International Journal of Nanomedicine)
Widening health inequalities related to Type 1 diabetes care in children and young people in the UK– a time to act now
The authors urge that research into barriers of access to technology for T1D in CYP in the UK specifically looking at provider bias, systemic issues within the health system, and individual and family factors are conducted with urgency (Diabetic Medicine)
Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes
Intralymphatic administration of GAD-alum is a simple, well-tolerated treatment that together with vitamin D supplementation seems to preserve C-peptide in patients with recent-onset T1D carrying HLA DR3-DQ2. This constitutes a disease-modifying treatment for T1D with a precision medicine approach (Diabetes Care)
Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial
Intralymphatic administration of GAD-alum is a simple, well-tolerated treatment that together with vitamin D supplementation seems to preserve C-peptide in patients with recent-onset T1D carrying HLA DR3-DQ2. This constitutes a disease-modifying treatment for T1D with a precision medicine approach (Diabetes Care)
Short‐term Intensive Insulin as Induction and Maintenance Therapy for the Preservation of Beta‐cell Function in early Type 2 Diabetes (RESET IT): A 2‐year Randomized Controlled Trial
Although initial induction IIT induces metabolic improvement, subsequent repeat courses of IIT every 3‐months do not further enhance the effect of metformin maintenance therapy on beta‐cell function (Diabetes, Obesity and Metabolism)
Motivational Stage at CGM Initiation in Pediatric Type 1 Diabetes is Associated with Current Glycemic Control but does not Predict Future CGM Adherence or Glycemic Control
SOCRATES can categorize children with type 1 diabetes and their parents into motivational stages. While motivational stage was associated with glycemic control at trial entry, it did not predict future diabetes-related behaviour or HbA1c (Canadian Journal of Diabetes)
Therapeutic inertia in the management of dyslipidaemia and hypertension in incident type 2 diabetes and the resulting risk factor burden: real‐world evidence from primary care
Significant delay in initiating cardioprotective therapies was observed, time to first prescription was similar in primary prevention people irrespective of ASCVD risk status across all T2DM diagnosis age groups, resulting in poor risk factor control over 2‐years follow‐up (Diabetes, Obesity and Metabolism)
Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial
The combination of anti-IL-21 and liraglutide could preserve β-cell function in recently diagnosed type 1 diabetes. The efficacy of this combination appears to be similar to that seen in trials of other disease-modifying interventions in type 1 diabetes, but with a seemingly better safety profile (The Lancet Diabetes & Endocrinology)
Cardiovascular impact of new drugs (GLP-1 and gliflozins): the ABCD position statement
ABCD: The position statement is now on-line in The British Journal of Diabetes
The comparative effects of intensive glucose lowering in diabetes patients aged below or above 65 years: results from the ADVANCE trial
Our results suggest that an intensive glycaemic control strategy to reduce HbA1c to 6.5% provided broadly similar benefits and harms and may be recommended for older, as well as younger, patients (Diabetes, Obesity and Metabolism)
Processes Underlying Glycemic Deterioration in Type 2 Diabetes: An IMI DIRECT Study
Stabilization of a single trait among insulin sensitivity, β-cell function, and insulin clearance may be relevant to prevent progression (Diabetes Care)
ABCD and ABHI Position on Insulin Pumps
ABCD and ABHI have released a joint position statement “Supporting Management of People with diabetes using Out-of-Warranty Pumps while Ensuring Appropriate Patient Choice”
- 1
- 2
- 3
- …
- 24
- Next Page »
Glycosmedia is also available as an App: